NCT05242146终止1 期
A Phase 1b/2, Open-label Dose Escalation With Expansion Study of GB5121 in Adult Patients With Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma or Primary Vitreoretinal Lymphoma, With a Phase 2 Open-label Single Dose Level Study of GB5121 in Adult Patients With Relapsed/ Refractory Primary Central Nervous System Lymphoma
GB005, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.14 个研究点 分布在 6 个国家目标入组 12 人开始时间: 2022年5月24日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- 入组人数
- 12
- 试验地点
- 14
- 主要终点
- Phase 1b Dose Escalation - Optimal Biologic Dose and/or Maximum Tolerated Dose and Recommended Phase 2 Dose
研究概览
简要总结
The STAR CNS trial is a 3-part study, comprising a phase 1b dose escalation, dose expansion, and a phase 2, to assess the safety, tolerability, dose-limiting toxicity(ies), maximum tolerated dose, and/or optimal biological dose, determine the recommended phase 2 dose, preliminary anti-tumor activity and efficacy of the recommended phase 2 dose of GB5121.
详细描述
Note: The Phase 1b dose expansion and Phase 2 parts of the study were not initiated.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have histologically/cytologically confirmed primary central nervous system lymphoma (PCNSL), primary vitreoretinal lymphoma (PVRL), or CNS-only involvement of a systemic B-cell lymphoma.
- •All patients must have relapsed/refractory disease and must have received all possible standard-of-care CNS-directed therapy treatment regimens or patients for which further standard-of-care treatment options are contraindicated or declined.
- •Patients must be able to tolerate gadolinium-enhanced magnetic resonance imaging (MRI) scans, or contrast-enhanced computed tomography (CT).
- •Patients with parenchymal lesions must have baseline imaging (gadolinium-enhanced MRI or if contraindicated, contrast-enhanced CT, of the brain) within 28 days prior to first study drug dose. For patients with leptomeningeal disease only, cerebrospinal fluid (CSF) cytology must document lymphoma cells and/or imaging findings consistent with leptomeningeal disease after informed consent and prior to first study dose (at the discretion of the Investigator).
- •Patients with parenchymal lesions must have measurable disease (disease that has at least one lesion on imaging ≥ 10 mm in the longest diameter) on imaging (gadolinium-enhanced MRI or if contraindicated, contrast-enhanced CT, of the brain) prior to first study dose.
- •Patients must be able to tolerate and consent for a lumbar puncture and/or have pre-existing placement of an Ommaya reservoir, unless clinically contraindicated.
- •Patients must have a performance status of 0, 1, or 2 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale.
- •Demonstrate adequate bone marrow and organ function.
排除标准
- •Patients are concurrently using other approved or investigational antineoplastic agents.
- •Patients have an active concurrent malignancy requiring active therapy.
- •Patients are allergic to components of the study drug.
- •Patients have a known bleeding diathesis (eg, von Willebrand's disease) or hemophilia.
- •Patients who require therapeutic anticoagulation, including dual antiplatelet agents. Patients who have received therapeutic anticoagulation, including dual antiplatelet agents, within 5 half-lives of the anticoagulant or 14 days, whichever is longer, prior to starting the study drug. Patients who require the use of antiplatelet agents should be discussed with the Sponsor's Medical Monitor.
- •Patients have significant abnormalities on screening electrocardiogram (ECG) and active and significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, uncontrolled hypertension, valvular disease, pericarditis, or myocardial infarction within 6 months of screening.
- •Patients with any of the following will be excluded:
- •A marked baseline prolongation of QT/QTc interval (eg, repeated demonstration of a QTc interval > 480 ms [CTCAE grade 2]) using Frederica's QT correction formula.
- •A history of additional risk factors for Torsades de Pointes (eg, heart failure, hypokalemia, family history of long QT syndrome).
- •The use of concomitant medications that prolong the QT/QTc interval.
- •Patients are known to have a history of active or chronic infection with hepatitis C virus (HCV), hepatitis B virus (HBV), as determined by serologic tests.
- •Known history of infection with human immunodeficiency virus (HIV).
- •Patients are known to have an uncontrolled active infection.
- •Patients have a history of stroke or intracranial hemorrhage within 6 months prior to enrollment.
- •Patients have a life-threatening illness, medical condition, or organ system dysfunction that, in the opinion of the Investigator, could compromise the subject's safety or put the study outcomes at undue risk.
- •Women who are pregnant or nursing (lactating).
研究组 & 干预措施
GB5121
Experimental
GB5121 orally twice per day (BID)
干预措施: GB5121 (Drug)
结局指标
主要结局
Phase 1b Dose Escalation - Optimal Biologic Dose and/or Maximum Tolerated Dose and Recommended Phase 2 Dose
时间窗: From first dose up to approximately 36 months
Phase 1b Dose Expansion - Incidence of Adverse Events
时间窗: From first dose until 28 days after the last dose of GB5121
Phase 2 - Objective Response Rate According to International Primary CNS Lymphoma Collaborative Group (IPCG) Criteria by Blinded Independent Central Review Committee (BICR)
时间窗: From Study Day 1 until disease progression assessed by the Investigator per IPCG criteria, unacceptable toxicity, or discontinuation, up to approximately 36 months
Phase 1b Dose Escalation - Serious Adverse Events
时间窗: From consent until 28 days after the last dose of GB5121
Phase 1b Dose Expansion - Serious Adverse Events
时间窗: From consent until 28 days after the last dose of GB5121
Phase 1b Dose Escalation - Incidence of Adverse Events
时间窗: From first dose until 28 days after the last dose of GB5121
Phase 1b Dose Escalation - Dose Limiting Toxicity(ies)
时间窗: From Cycle 1, Day 1 through Cycle 1, Day 28 inclusive, Each Cycle=28 days
次要结局
- Phase 2 - Confirmed Complete Response by BICR Committee(From Study Day 1 until disease progression assessed by the Investigator per IPCG criteria, unacceptable toxicity, or discontinuation, up to approximately 36 months)
- Phase 2 - Median Overall Survival(From Study Day 1 until death, unacceptable toxicity, or discontinuation, up to approximately 36 months)
- Phase 2 - Incidence of Serious Adverse Events(From consent until 28 days after the last dose of GB5121)
- Phase 1b Dose Expansion - Objective Response Rate According to IPCG Criteria by Investigator Assessment(From Study Day 1 until disease progression assessed by the Investigator per IPCG criteria, unacceptable toxicity, or discontinuation, up to approximately 36 months)
- Phase 2 - Progression-Free Survival at Week 24(From Study Day 1 until Week 24)
- Phase 2 - Objective Response Rate According to the IPCG Criteria by Investigator Assessment(From Study Day 1 until disease progression assessed by the Investigator per IPCG criteria, unacceptable toxicity, or discontinuation, up to approximately 36 months)
- Phase 2 - Incidence of Adverse Events(From first dose until 28 days after the last dose of GB5121)
- Phase 2 - Duration of Response by BICR Committee(From first observation of complete response, unconfirmed complete response or partial response until disease progression assessed by the Investigator per IPCG criteria, unacceptable toxicity, or discontinuation, up to approximately 36 months)
- Phase 2 - Median Progression-Free Survival(From Study Day 1 until disease progression assessed by the Investigator per IPCG criteria, unacceptable toxicity, or discontinuation, up to approximately 36 months)
研究者
研究点 (14)
Loading locations...
相似试验
已完成
1 期
TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced CancersMetastatic Castration Resistant Prostate CancerSquamous Cell Carcinoma of Head and NeckHepatocellular CarcinomaNon-small Cell Lung CancerRenal Cell CarcinomaUrothelial CarcinomaGastroEsophageal CancerPancreatic CancerSarcomaColorectal CancerTriple-Negative Breast CancerCholangiocarcinomaNCT03829436Tempest Therapeutics38
终止
1 期
A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of SLC-3010 Monotherapy and in CombinationAdvanced Solid TumorNCT05525247Selecxine27
进行中（未招募）
1 期
Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) MutationsNon-Small Cell Lung Cancer (NSCLC)Metastatic Non-Small Cell Lung CancerAdvanced Non-Small Cell Lung CancerHER2 Exon 20 MutationsEGFR Exon 20 MutationsEGFR Uncommon Mutations, Including G719X and S768INCT05364073ArriVent BioPharma, Inc.160
招募中
1 期
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid TumorsMetastatic Solid TumorAdvanced or Metastatic Solid TumorNCT06270706Pliant Therapeutics, Inc.124
进行中（未招募）
1 期
IMX-110 in Patients With Advanced Solid TumorsSolid Tumor, AdultAdvanced Solid TumorsBreast CancerOvarian CancerPancreatic CancerNCT03382340Immix Biopharma Australia Pty Ltd70